Cape Charles Main Street has received $20,000 from the Virginia Tourism Corporation’s (VTC) Recovery Marketing Leverage Program (RMLP).
The grant is purported to aid towns whose existence relies on tourism dollars. The monies are to be used to attract more visitors by matching local marketing dollars of the state grants funds.
$1.9 million in matching grant funds were awarded to 161 local tourism initiatives through this year.
Cape Charles Main Street will use the VTC Recovery Marketing Leverage grant funds to drive more people to visit Cape Charles through the shoulder seasons (Fall, Winter, Spring), no matter the impact on the lives of local residents and neighborhoods.
Thomy says
New 3 letter brand LDM. Locals don’t matter when it involves tourist. All we do is live here and pay taxes.
Note: So much truth in this statement.
Chicken Little says
Why do we want to drive tourists to Cape Charles they will only increase the risk of COVID infections. We need to keep Cape Charles Safe. Continue the lockdowns until there are no more COVID cases reported on the planet. Keep the community safe. Tourists stay home and infect your own community.
MJM says
Oh Good Grief ! Lockdowns until there are no more cases on the planet ?? Ha ! That’s a good one ! Your pen name sure seems to fit you. United Airlines is already shipping the vaccination to strategic locations for distribution. The FDA is going to approve it’s use 12/10. The first inoculations start the next day. We will all start to get our lives back as this process begins. If you wish to be afraid you have that right. On the other hand I wish to believe the FDA and enjoy this 2 stage vaccine like every other vaccination I have ever received. I have had only positive results from every one of them. So do most others. I also know we die if our businesses and way of life die. Get ready to make your choice. I ( sr. citizen with previous bronchial problems) hope to have my first of the 2 shots by 2/21.
Paul Plante says
POINT I:
CNBC
“Trump Covid vaccine czar says side effects ‘significantly noticeable’ in 10% to 15% of recipients”
Berkeley Lovelace Jr. @BerkeleyJr
Published Tue, Dec 1 2020
“The longer, more important kind of adverse events such as some autoimmune disease or others have not been reported in a different way between the placebo group and the vaccine group in these two trials, which is very reassuring,” Dr. Moncef Slaoui, who is leading the Trump administration’s Covid-19 vaccine program Operation Warp Speed, told The Washington Post.
“I always make sure we say that [while] we know the short term and I’m going to call it midterm effects of the vaccine is now well understood, the very long-term safety is not yet understood by definition.”
******
Jump right on that stuff and let us know how it works out for you, MJM:
Transverse Myelitis, Possible Adverse Reaction to COVID-19 Vaccine, Explained
September 10, 2020
Peter Wehrwein
The symptoms of the adverse event that led to the pause in Astra Zeneca’s COVID-19 vaccine trial are reportedly consistent with transverse myelitis. although the diagnosis has not been confirmed.
It is still unclear whether the adverse event that caused AstraZeneca to pause enrollment in its COVID-19 vaccine trial was transverse myelitis or not.
The New York Times is reporting this morning that in a statement to reporters yesterday an AstraZeneca spokesperson said the individual did not have a confirmed [emphasis added] case of transverse myelitis.
The newspaper reported two days ago that an anonymous source said a woman in the United Kingdom who had the possible adverse reaction to the vaccine had received a diagnosis of transverse myelitis.
Stat, which broke the story that the trial had been put on hold, reported yesterday that company’s CEO, Pascal Soriot, told investors in a conference call today that the symptoms of the woman whose illness led the company to pause of the trial are consistent with transverse myelitis, although in the same story the biotech news site reported that diagnosis had not been confirmed.
The Wall Street Journal reported yesterday that a form from July that was posted on an international registry of clinical trials said a study volunteer had developed symptoms of transverse myelitis.
Whether or not the adverse event is confirmed as a case of transverse myelitis or not, the news over the last few days has asking a lot of questions about transverse myelitis.
Here is some information for people who are unfamiliar with it:
What is transverse myelitis?
In simple terms, it is inflammation of the spinal cord.
Wolters Kluwer UpToDate, the database of reviews of medical topics, describes transverse myelitis as a “mixed inflammatory disorder that affects neurons, axons, and oligodendrocytes [the cells that produce myelin] and myelin.”
A 2010 “clinical practice” article in the New England Journal of Medicine described the “pathological hallmark” of the condition as being the “focal collection of lymphocytes and monocytes with varying degrees of demyelination, axonal injury and astroglial and microglial activation within the spinal cord.”
Why is it called transverse myelitis?
Myelitis is the medical term for inflammation of the spinal cord.
In some accounts, the modifier transverse is explained as referring to the pattern of symptoms that go across the body.
But the better explanation is that transverse refers to the transverse, or horizontal, plane of the spinal cord and the fact that the inflammation is usually limited to a relatively small area of the spinal cord, not its whole length.
Transverse also refers to the fact that both the ascending (that carry sensory messages to the brain) and descending (which direct voluntary movement) tracts of the spinal cord are affected.
What causes transverse myelitis?
There have been several case reports suggesting that COVID-19 itself could trigger transverse myelitis.
For example, in a letter published in May in the Journal of Neurology, German clinicians described the case of a 60-year-old man who recovered quickly from COVID-19 pneumonia but then developed symptoms suggestive of transverse myelitis three days after he was discharged.
In a nontechnical explanation on its website, the Johns Hopkins Transverse Myelitis Center says the four “classic” symptoms are weakness in the arms and legs, sensory symptoms such as numbing and tingling, pain and discomfort, and bladder dysfunction, bowel motility problems, or both.
MJM says
Get with Jim Baugh and compose a direct to market ad campaign thru the lens starring local beauty and local business with this money. Promote our highlights and the fact that Cape Charles is closer and less crowded than OBX and Va. Beach via website(s) on the internet. Challenge those 2 vacation locations for tourists dollars. They aren’t going to give up their markets. Cape Charles has to take them. Get with The Chamber of Commerce ? Have fun in the ads/pictures. Please don’t put up more signs that are unnecessary and detract from the beauty. Let Jim be slick, colorful and creative to catch the eye. In case you’re wondering, No I don’t know Jim and don’t believe I ever met him.
Useysly says
Those grant monies go toward helping our businesses remain vital through the long winter months – something we should all appreciate. If we want to continue to have these lovely shops to visit and to obtain beneficial services made available from the revenue generated from Transient Occupancy and Sales taxes, then we will need to continue to attract visitors to our beautiful little town. I, for one, welcome well behaved families and retirees to bring more life onto Mason Ave. And that’s whose coming! It will be a long, long time – if ever – that we have to worry about becoming another OBX or VA Beach! I worry more about the escalating prices of housing which will, to an even a greater degree, reduce the amount of affordable housing in Cape Charles. It will become a town of wealthy white priviledged residents with no diversity. We’ll become inbred!
Paul Plante says
Hasn’t that inbreeding already happened to a great degree?